Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H32N6O11 |
Molecular Weight | 580.5445 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=C(OCC[C@H](NC1=O)C(=O)NCC(O)=O)C=CC(=C2)[N+]([O-])=O
InChI
InChIKey=DVJXNXPFYJIACK-ULQDDVLXSA-N
InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1
Molecular Formula | C24H32N6O11 |
Molecular Weight | 580.5445 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tavilermide (also known as MIM-D3) was developed as a tyrosine kinase TrkA receptor agonist for the treatment of patients with dry eye. The drug was studied in phase III clinical trial in treating the signs and symptoms of dry eye. In addition, was assumed that tavilermide could be studied for glaucoma.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23836957
A total of 150 dry eye patients were randomized 1:1:1 to study medication (1% MIM-D3 (TAVILERMIDE), 5% MIM-D3, or placebo) and dosed twice daily (BID) for 28 days.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:40:17 GMT 2023
by
admin
on
Sat Dec 16 05:40:17 GMT 2023
|
Record UNII |
NMG938VJ6T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10161
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
9808372
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL3544981
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
NMG938VJ6T
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
263251-78-1
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
DTXSID00180937
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
BC-126
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
Tavilermide
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
C174759
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
300000034366
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY | |||
|
DB12441
Created by
admin on Sat Dec 16 05:40:17 GMT 2023 , Edited by admin on Sat Dec 16 05:40:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|